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Summary statement 
In this study, we show that the loss of the epilepsy-related gene Frrs1l in mice causes a 
dramatic reduction in AMPA receptor levels at the synapse. This change elicits severe motor 
and coordination disabilities, hyperactivity and cognitive defects, with some evidence of 




Loss of function mutations in the human AMPA receptor-associated protein, ferric chelate 
reductase 1-like (FRRS1L), are associated with a devastating neurological condition 
incorporating choreoathetosis, cognitive deficits and epileptic encephalopathies. Furthermore, 
evidence from overexpression and ex vivo studies have implicated FRRS1L in AMPA receptor 
biogenesis, suggesting that changes in glutamatergic signalling might underlie the disorder. 
Here, we investigated the neurological and neurobehavioural correlates of the disorder using 
a mouse Frrs1l null mutant. The study revealed several neurological defects that mirrored 
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spectrum of early-onset motor deficits with no progressive, age-related deterioration. 
Moreover, Frrs1l-/- mice were hyperactive irrespective of test environment, exhibited working 
memory deficits and displayed significant sleep fragmentation. Longitudinal 
electroencephalographic recordings also revealed abnormal EEG in Frrs1l-/- mice. Parallel 
investigations into disease aetiology identified a specific deficiency in AMPA receptor levels in 
the brain of Frrs1l-/- mice, while the general levels of several other synaptic components 
remained unchanged with no obvious alterations in the number of synapses. Furthermore, we 
established that Frrsl1 deletion results in an increased proportion of immature AMPA 
receptors, indicated by incomplete glycosylation of GLUA2 and GLUA4 AMPA receptor 
proteins. This incomplete maturation leads to cytoplasmic retention and a reduction of those 
specific AMPA receptor levels in the postsynaptic membrane.  Overall, this study determines, 
for the first time in vivo, how loss of FRRS1L function can affect glutamatergic signalling and 
provides mechanistic insight into the development and progression of a human hyperkinetic 





Ferric chelate reductase 1 like (FRRS1L) is a novel, highly conserved, brain specific protein 
whose functional characterisation has only recently been under investigation. Studies in 
patients have found nine families with recessive mutations in FRRS1L which result in severe 
intellectual disability, movement disorders, hypotonia and epilepsy (Madeo et al., 2016; 
Shaheen et al., 2016; Brechet et al., 2017). In some patients, these clinical symptoms are 
accompanied by neurodegeneration in the cortex and cerebellum. Several families have now 
been diagnosed with this devastating condition, arguing for the inclusion of this gene in the 
diagnostic screening for epilepsy and dyskinetic disorders (Carecchio and Mencacci, 2017). 
The dramatic clinical consequences of carrying mutations in this gene point to an important 
neurological function for FRRS1L, which has not yet been elucidated, hence challenging 
efforts in therapeutic development.   
Although named for its sequence similarity to ferric chelate reductase 1, FRRS1L has only a 
poorly characterised DOMON domain (DOpamine beta-MOnooxygenase N-terminal domain, 
IPR005018) and a transmembrane domain, with the ferric chelate reductase domain being 
absent, therefore its function is likely to be distinct from that of its namesake, FRRS1. Frrs1l is 
expressed in the central nervous system (CNS) and testis of adult mice and in developing 
embryonic forebrain (Madeo et al., 2016). Further expression analysis in the adult mouse brain, 
































midbrain, medium spiny neurons in the striatum, granule cells in the dentate gyrus and Purkinje 
cells in the cerebellum (Zeisel, A et al., 2018 preprint). Emerging studies have begun to 
unravel the role of FRRS1L in the CNS, importantly in AMPA receptor complex function. 
FRRS1L co-localises with Calnexin in the endoplasmic reticulum (ER) of rat hippocampal 
neurons (Brechet et al., 2017). Results of knockdown and exogenous overexpression studies 
in cultured hippocampal neurons suggest that FRRS1L, along with carnitine 
palmytoyltransferase 1c (CPT1C), is involved in the early stages of AMPA receptor complex 
biogenesis, binding to the core AMPA proteins, GLUA1-4, but dissociating before the final 
auxiliary proteins bind to make a functional receptor (Brechet et al., 2017). Furthermore, 
reduction of FRRS1L levels in cultured hippocampal neurons leads to an overall decrease in 
AMPA receptor levels, as well as to modifications in synaptic transmission. In addition, 
interactions with dynein complex proteins suggest a potential role for FRRS1L in dynein based 
AMPA trafficking (Han et al., 2017). 
AMPA receptors are essential ionotropic glutamate receptors and mediate much of the fast-
excitatory synaptic transmission in the brain. AMPA receptors are composed of four core 
proteins, GLUA1-4, which form a heterotetrameric complex at the centre of the receptor. 
Associated with this core complex are a variety of auxiliary subunits with distinct roles in the  
maturation of AMPA receptors  (Chen et al., 2000; Tomita et al., 2003; Kato et al., 2010; 
Schwenk et al., 2012, 2014; Erlenhardt et al., 2016). These auxiliary proteins have distinct 
roles in regulating the spatio-temporal activity of AMPA receptors, however many of these 
roles have yet to be elucidated.  
   
The majority of human variants in patients with homozygous mutations in FRRS1L are 
predicted to lead to a premature stop codon and loss of the transmembrane domain, 
consequently leading to a loss of function. A knockout of the murine Frrs1l gene (Frrs1ltm1b/tm1b) 
has been generated by the International Mouse Phenotyping Consortium (IMPC, 
http://www.mousephenotype.org/) to investigate the consequences of Frrs1l loss in vivo. Initial 
characterisation of this line uncovered a range of aberrant phenotypes including hyperactivity, 
abnormal gait, decreased grip strength and partial pre-weaning lethality (Koscielny et al., 2014; 
mousephenotype.org, accessed 01-06-2018). In the current study, we make use of this mouse 
line to explore its validity as a model and to investigate the phenotypic deficits in more depth. 
Moreover, we make use of this model to study whether a disturbance in AMPA receptor 
maturation is the mechanism underlying the pathology of the disorder providing new in vivo 


































Loss of Frrs1l results in increased neonatal lethality, smaller size and early onset motor 
deficits 
Frrs1l-/- mice are born at expected Mendelian ratios; milk is present in the stomach, breathing 
is apparently normal and it is not possible to visibly distinguish between Frrs1l-/- and wild-type 
littermates. However, >90% of Frrs1l-/- neonates die between 12 and 24 hours after birth. 
Analysis of numbers per genotype at weaning show a difference in expected ratios (p<0.0001), 
whereas at postnatal day 0 (P0) the ratio of genotypes is not significantly different to that 
expected (p=0.43) (Fig. 1A). Tissue was collected from any pups that were found dead in the 
first days after birth and genotyping carried out. We found mortality to be higher in Frrs1l-/- with 
a greater proportion of homozygotes being found dead than would be expected by chance if 
this was not a genotype effect (p<0.001). Gross pathology was performed on pups at P0 and 
no obvious abnormalities were found in 44 tissues examined (data not shown). Frrs1l-/- mice 
that survive past P2 continue to thrive to weaning and beyond. Five of the nine female 
homozygous mice were killed during the course of the study as they reached previously 
specified humane endpoints, including; seizure without full recovery (n=1), self-inflicted 
wounds and stereotypical behaviour (n=2), uncoordinated gait impinging on the ability to feed 
(n=1) and breathing difficulties (n=1).  
In order to confirm that homozygous mutant mice no longer express Frrs1l, we conducted 
qPCR assays with primers spanning all five exons of the gene, including the targeted exon 3. 
We confirmed no significant expression of Frrs1l in P0 and adult Frrs1l-/- brains compared to 
wild-type littermates (Fig. S1A and B). Of the Frrs1l-l- mice that survive to weaning, all show 
prominent reduced body weight when compared to littermate controls (P<0.05 from 6 months 
onwards) (Fig. 1B). However, the weight curve is not dissimilar to wild-type and does not show 
significant decline with age up to 14 months, suggesting a neurodevelopmental effect rather 
than a progressive wasting phenotype. Given the difference in body size, we further examined 
archived IMPC x-ray images and found that Frrs1-l- mice have a significantly shorter tibia 
length, and therefore smaller body size, than wild-type controls in both females (P<0.01) and 
males (P<0.05) (http://www.mousephenotype.org, 2015). IMPC data also show no differences 
in body composition or calorimetric measurements of metabolic rate. In some cases, several 
years after onset of symptoms, human patients carrying mutations in FRRS1L express 
cerebellar atrophy and other pathological alterations in the brain (Madeo et al., 2016). In Frrs1l-
/- cohorts, we found total brain weight to be approximately 10% less than wild-type controls 
(Frrs1l+/+ 0.459 ± 0.018 and Frrs1l-/- 0.417 ± 0.009) (p<0.05), however no gross anatomical 
pathologies were evident Moreover, brain size differences were not significant after 

































Animals that survived through early postnatal development were assessed using a focused 
battery of physiological, behavioural and motor function tests throughout adulthood. 
Motor phenotyping was carried out in order to determine whether Frrs1l-/- mice expressed 
abnormalities in movement and muscle force similar to those described in humans carrying 
FRRS1L mutations. We used a standard battery of tests including SHIRPA, grip strength and 
rotarod, followed by more complex testing of motor function using a horizontal ladder and a 
three week trial that measures progressive wheel running performance parameters. On visual 
inspection, Frrs1l-/- mice have an abnormal gait which is evident at weaning and, in SHIRPA 
testing, show additional significant differences from wild-type littermate controls when 
assessed at 3, 6 and 9 months of age (P<0.05, P<0.01 and P<0.001 respectively) (Table 1).  
Abnormalities highlighted in the SHIRPA test include; lack of co-ordination, demonstrated by 
inability to place feet correctly on a grid floor (p<0.001 at 9 months), loss of grip when climbing 
down a vertical grid (p<0.001 at 9 months), and reduced muscle force indicated by an 
increased incidence of limb grasping (p<0.01 at all time points) (Table.1 and Fig.1C). Limb 
grasping is also associated with defects in many neurological disorders, and it may indicate 
alterations in cortico-striatal circuits (Lalonde and Strazielle, 2011). 
 
We measured grip strength at 3, 6 and 9 months of age to confirm quantitatively that the loss 
of Frrs1l resulted in reduced ability to grip. Indeed, grip force in all four limbs was significantly 
reduced in Frrs1l-/- mice compared to wild-type controls (Fig. 1D). The effect remained 
significant even after correcting for weight differences (3 months p<0.05, 6 months p<0.05, 9 
months p<0.01). This loss of ability to grip is expressed from an early age without further 
deterioration, suggesting a developmental non-progressive phenotype.  
Next, we assessed gait and motor co-ordination by performing three complementary tests at 
a single time point for each: a horizontal ladder challenge (Locotronic), a rotarod test and a 
wheel running paradigm. In the Locotronic challenge, Frrs1l-/- mice showed an increased 
frequency of errors (misplacement of feet) whilst moving along the horizontal ladder when 
compared to their littermate controls (p<0.01) (Fig. 1E). This elaborates upon the previous 
observations in the SHIRPA test where homozygotes had a higher number of instances of feet 
falling through the bars of the grid.  
Supporting these data, Frrs1l-/- mice also had a shorter latency to fall when placed on an 
accelerating rotarod (p<0.05) (Fig. 1F). In the motor function assessment by wheel running, 
no differences were observed between Frrs1l-/- and wild-type mice during the first two weeks. 
In the third week, the standard wheel was removed and replaced by a complex wheel with 
rungs missing at uneven intervals. After the new challenge was introduced Frrs1l-/- were unable 
to run at all, showing a drop in running attempts to almost zero for the remainder of the third 
































Thus, all tests evidence that mice lacking the Frrs1l gene suffer from a dramatic loss in grip 
strength with loss of motor co-ordination and motor disabilities from an early age.   
 
Frrs1l-/- mice are hyperactive, have cognitive deficits and abnormalities in immobility 
defined sleep 
Previous IMPC-based assessment of these mice had indicated a hyperactivity phenotype. To 
confirm and further define this hyperactivity, mice were assessed at a number of time-points 
in group-housed conditions in the home cage to evaluate their activity continuously in an 
undisturbed, non-stressful environment. Frrs1l-/- mice displayed increased activity when 
recorded at 10 weeks of age throughout both light and dark phases (p<0.05 light, p<0.0001 
dark) and increased activity at six and nine months in the dark phase only (p<0.05 at both time  
points) (Fig. 2A and B). These home cage data indicate the hyperactivity is not a consequence 
of being introduced to a novel environment.  
In the novel environment of the open field test at a single time point, Frrs1l-/- mice exhibited 
increased activity in the whole arena demonstrated by a greater total distance moved (p<0.01) 
(Fig. 2C) and an increased velocity (p<0.01) (Fig. 2D), supporting the hyperactivity phenotype 
observed in the home cage analysis. The frequency to enter the centre of the arena and 
velocity in the centre of the arena were also significantly increased (p<0.05), however distance 
moved and duration in the centre were not different between Frrs1l-/- and wild-type, indicating 
that the mice are hyperactive, however we cannot rule out the contribution of an altered anxiety 
state in mutants (Fig. S2A).  
 
Learning disabilities are among the common features associated with intellectual disability, 
such as those seen in patients carrying mutations in FRRS1L. In the null mice, we evaluated 
working memory using the Y-maze forced alternation test. Interestingly, Frrs1l-/- mice showed 
no preference for the novel arm (Fig. 2E) (p<0.05) suggesting a working memory deficit. 
Previous studies have demonstrated that defects in AMPA receptor composition are 
associated with both intellectual disability and perturbed sleep patterns (Davies et al., 2017).  
Since FRSS1L has been proposed to play a role in AMPA receptor assembly, we assessed 
sleep status in Frrs1l-/- animals using passive infrared movement tracking (PIR)(Brown et al., 
2016) which scores sleep using a periods of immobility as a behavioural sleep correlate. The 
total immobility defined sleep of Frrs1l-/- animals was significantly less than wild-type controls 
in the dark phase of the light cycle (time spent asleep in dark p=0.0002) (Fig. 2F). Additionally, 
the average length of sleep bouts was significantly reduced in Frrs1l-/- animals (average sleep 
bout length p=0.001). Analysis of sleep bout length in the light and dark phases of the light 
cycle revealed that Frrs1l-/- animals had a significant reduction in sleep bout length in the dark 
































in dark p=0.00001, average sleep bout length in light p=0.079) (Fig. 2G). Interestingly, Frrs1l-
/- mice show no overt changes in circadian period or entrainment (data not shown).  
We also examined the IMPC archive data on the Fear Conditioning paradigm,  a test used to 
measure cognitive abilities, specifically those associated with non-declarative memory 
formation (LaBar and Cabeza, 2006). Mice lacking FRRS1L have deficits in cued but not 
contextual fear conditioning, demonstrating an inability to learn the association between a tone 
and an aversive stimulus and therefore an impairment in implicit memory (Fig 2H). 
 
 
Loss of Frrs1l causes abnormal EEG 
Mutations in FRRS1L are associated with epileptic encephalopathy. Behavioural seizures 
were observed during phenotyping on several occasions, consisting of episodes of 
behavioural arrest and lordotic posture in Frrs1l-/- animals as well as one mouse dying during 
a generalized convulsion. We carried out EEG recordings in Frrs1l-/- animals to ascertain 
whether the episodes seen could represent seizures. After the implantation of EEG 
transmitters in adult mice (n=2 Frrs1l/+/+, n=3 Frrs1l-/-, and n=2 C57BL/6NTac), we recorded 
EEG activity in their home-cage environment for 5 to 15 days.  
 
Although we did not capture discrete electrographic seizures Frrs1l-/- mice exhibited clear 
evidence of encephalographic abnormalities that were not observed in wild type controls 
(C57BL/6NTac and Frrs1l/+/+ animals) (Fig. 3). We are aware of the limitations of this 
assessment and quantifiable analysis of EEG warrants further investigation. These results are 
consistent with the view that loss of Frrsl1 leads to a profound encephalopathy.  
 
Decreased AMPA receptor protein levels in Frrs1l-/- brain  
In order to understand the mechanisms underlying the neurological and behavioural deficits 
described above, we investigated whether AMPA receptor levels were altered in vivo as a 
consequence of Frrs1l deletion, as suggested in earlier in vitro studies (Brechet et al., 2017)). 
We first examined whether the deletion of Frss1l would cause alterations in the gene 
expression levels of the four core AMPA receptor genes (Gria1, Gria2, Gria3 and Gria4) and 
found no differences between wild-type and Frrs1l-/- mice either in P0 brain or in adult brain 
(Fig.S1C and Fig.4A). We next examined levels of three core AMPA receptor proteins (GLUA1, 
GLUA2 and GLUA4) in P0 brain and in 14 month-old cerebellum. In adult cerebellum, GLUA1, 
GLUA2 and GLUA4 levels were all significantly reduced in Frrs1l-/- compared to wild-type 
controls (p<0.001, p<0.01, p<0.001 respectively) (Fig. 4B and C). In P0 brain only GLUA1 was 
significantly reduced, while alterations in immunoreactive band mobility were noted for both 
































 To confirm that there was a specific loss of AMPA receptors in homozygotes rather than a 
general loss in synaptic number, we compared the levels of several standard synaptic proteins 
in adult cerebellum and P0 brain.  Interestingly, we found no differences in expression of any 
of the synaptic proteins assessed (CAMKII, SNAP25, PSD95 and NMDA receptor) at any time 
point between wild-type and Frrs1l-/- brains (Fig. 4D-F and S3C and D). To investigate further, 
we counted the proportion excitatory synapses in the hippocampus and found no differences 
in synapse number between wild-type and Frrs1l-/- brains (Fig. S4). Collectively, these data 
show that there is a significant reduction in AMPA receptor subunit levels present in adult 
Frrs1l-/- mice while synaptic numbers and levels of several key synaptic markers remain 
unchanged. Similar changes in protein level are observed in Frrs1l-/- P0 brain, which points to 
a developmental defect rather than a progressive degenerative change.  
 
AMPA receptor glycosylation is incomplete leading to cytoplasmic retention in Frrs1l-/- 
mice 
Given that AMPA receptor protein levels were reduced while their transcriptional activity was 
unaffected, we concluded that these deficits in Frrs1l-/- brain are most likely due to specific 
alterations in translational or posttranslational mechanisms. Interestingly, we observed that 
GLUA2 and GLUA4 band mobilities in western blots differ in wild-type and Frrs1l-/- mice, with 
a more diffuse band in GLUA2 wild-type compared to in Frrs1l-/- and a faster-running band 
seen in GLUA4. These differences could be related to differences in post-translational 
modification caused by a deficiency in this process in Frrs1l-/- mice. As part of the maturation 
process of the AMPA receptor complex, the glycosylation of AMPA receptors goes through a 
series of modifications. Initially N-linked high mannose glycans are added to GLUA2 and 
GLUA4 in the endoplasmic reticulum (ER). Subsequently, AMPA receptor complexes are 
transported to the Golgi apparatus where glycans are clipped and modified to create more 
complex N-linked glycans. Assessing glycosylation state allows us not only to determine the 
extent of AMPA receptor glycosylation but also to establish the subcellular localisation of the 
AMPA receptor complex (Tucholski et al., 2013, 2014).  
We assessed the glycosylation status of GLUA2 and GLUA4 receptor subunits in control and 
mutant samples. Lysates from adult cerebellum were digested with endoglycosidase H 
(ENDO-H) and peptide:N-glycosidase F (PNGase) enzymes which cleave either immature 
glycosylated moieties, such as high mannose glycans, or all glycosylated forms, respectively 
(Fig. 5A). We found that, when digested with PNGase, all immunoreactive bands showed an 
apparent size shift, indicating that the subunits are typically glycosylated in both wild-type and 
Frrs1l-/- brain. When incubated with ENDO-H, in wild-type mice, only a small proportion of the 
































Therefore the majority of GLUA2 and GLUA4 in wild-type is insensitive to ENDO-H and thus 
must be maturely glycosylated. Conversely, in Frrs1l-/- a greater proportion (p<0.01) of the 
GLUA2 and GLUA4 was digested with ENDO-H, amounting to approximately 65% of GLUA2 
and 45% of GLUA4 total protein. This demonstrates a higher level of immature glycosylation 
of the receptor subunits in the absence of FRRS1L. Based on previous work following AMPA 
receptor localisation and glycosylation (Tucholski et al., 2013, 2014), this result also suggests 
that GLUA2 and GLUA4 AMPA receptor processing is stalled at the level of the Golgi 
apparatus in Frrs1l-/- mice.  
 
This increase in immaturely glycosylated AMPA receptors in Frrs1l-/- mice might result in a 
reduction in receptor levels at the synaptic membrane. To investigate, we carried out synaptic 
fractionation to determine the proportional levels of AMPA receptor in the cytoplasmic and 
post-synaptic membrane fractions of adult forebrain. These data show that more than double  
 
the amount of both GLUA2 and GLUA4 are retained in the cytoplasm of Frrs1l-/- compared to 
wild-type, leading to a reduction in the post-synaptic fraction (Fig. 5B). Interestingly, for 
GLUA1, levels were proportionally lower in the post-synaptic fraction in mutant brain without 
evidence for retention in the cytoplasmic fraction. Additionally, NMDAR levels in the post-
synaptic fraction were not affected by Frrs1l deficiency (Fig 5C).   
In conclusion, these results reveal that the loss of FRRS1L leads to a specific reduction in the 
levels of the AMPA receptor subunit proteins at the synapse in vivo without obvious changes 
in other synaptic components. Functional FRRS1L is necessary for the mature glycosylation 
of at least GLUA2 and GLUA4. The mechanism through which Frrs1l effects glycosylation 
could conceivably occur through two routes, either through control of glycosylation by Frrs1l, 
or through control of earlier maturation processes, which when disrupted, result in incomplete 
processing, maturation and consequently glycosylation. Loss of FRRS1L leads to incomplete 
post-translational processing of AMPA receptors, increased retention of AMPA receptors in 
the cytoplasmic fraction and, consequently, a decrease in levels of functional AMPA receptors 




In previous work we described several families with homozygous mutations in FRRS1L 
(Madeo et al., 2016). The main symptoms in the affected children are encephalopathy, 
epilepsy and progressive choreoathetosis. All children have severe intellectual disability with 
no expressive speech, impaired volitional movement and hypertonia. Initial hyperkinesia, 
































only recently characterized, although it is expected that there will be more cases in the near 
future, especially considering the gene is now included in the screening for infantile epilepsy 
and dyskinesia (GTR test ID GTR000551789.3).   
 
Our data demonstrate that complete lack of Frrs1l has substantial effects on post-natal 
survival, as well as body weight, motor co-ordination, activity, immobility defined sleep, effects 
on cognition and abnormal EEG. Anomalies are present from an early age with no progressive 
deterioration, suggesting a neurodevelopmental defect, rather than an age-associated 
neurodegenerative disorder. Abnormalities in grip strength may be related to neurological 
function and correlates with hypotonia seen in human patients. The reduced grip strength 
might be a reflection of a neurogenic alteration rather than myogenic weakness. 
Similarly, human patients with mutations in FRRS1L have primarily a CNS phenotype, 
however they also display hypotonia of unknown origin (Madeo et al., 2016), which 
corresponds with the phenotype seen in the Frrs1l-/- mice. Furthermore, there is evidence from 
other mouse models that neurological defects can cause reduction in grip strength through 
neurological mechanisms rather than muscle weakness, for example mice with Grin1 point 
mutations have NMDA receptors with reduced function and display similar reductions in grip 
strength to Frrs1l-/- mice (Ballard et al., 2002).  Interestingly our data indicates that Frrs1l-/- mice 
show sleep disturbances. Although disturbances in sleep have not been documented in human 
patients with mutations in FRSS1L, it is well known that sleep disruption is often a feature of 
numerous neurological disorders, particularly epileptic disorders (Crespel, Baldy-Moulinier and 
Coubes, 1998; Kothare and Kaleyias, 2010). However we do note that the sleep scoring used 
in this study is based upon a behaviourally defined sleep correlate for sleep rather than 
electrophysiological metrics. Further studies using such metrics would provide invaluable 
insight regarding the details of these sleep changes and how they may relate to additional 
phenotypes.  
We report the incidental occurrence of behavioural seizures in these mice, however we were 
unable to capture conclusive seizure patterns on EEG recording, which instead showed 
evidence of encephalographic abnormalities. Thus, all these phenotypic features resemble the 
symptoms seen in patients carrying homozygous mutations in the FRRS1L gene, making 
these mice a very useful model of disease. The use of these mice allowed us to provide 
compelling in vivo evidence that FRRS1L is critical for AMPA receptor complex maturation, 
defects in which result in dramatic phenotypic effects in mice.  
 
In Frrs1l-/- mice we found a highly significant reduction in the levels of core AMPA receptor 
proteins from birth through to adulthood, and importantly, AMPA receptor subunits lack 
































vivo evidence that FRRS1L is crucial for the correct biogenesis and maturation of AMPA 
receptors, which elicits dramatic motor alterations, dyskinesia phenotypes, and abnormal 
electrographical activity in Frrs1l-/- mice. 
 
Previous work using a CRISPR/Cas9 deletion of Frrs1l in mouse primary neurons shows that 
it leads to an overall reduction in GLUA1 levels (Han et al., 2017).  Here we confirm that GLUA1 
levels are lower in vivo but we extend this observation to other GLUAs. Crucially, we show that 
the low AMPA receptor levels are not a consequence of degeneration nor are they associated 
with a general reduction in synaptic number in Frrs1l-/- mice. Thus the role of FRSS1L seems 
to be specific in the maturation of AMPA receptor complexes. Importantly we found that it is 
not only the levels of AMPA receptors that are low, but also their maturation (glycosylation) 
and location at synapses. AMPA receptors which are not fully glycosylated are not functional 
(Tomita et al., 2003; Tucholski et al., 2014), and so the presence of functional receptor 
complexes in the membrane are substantially deficient in mutants. We also provide evidence 
that FRSS1L has a critical role in the glycosylation/maturation of GLUA2 and GLUA4. It is 
interesting to note that the glycosylation of GLUA2 and GLUA4 is not totally abolished, 
indicating that there could be partial compensation for FRRS1L by another protein or perhaps 
a parallel mechanism, independent of FRRS1L, which may be involved in AMPA receptor 
biogenesis.  
 
Supporting these data, the Frrs1l-/- mouse phenotype resembles that of null mutations in other 
genes associated with synthesis, transport and stability of AMPA receptors, such as Cpt1c 
(Carrasco et al., 2013), Shank3 (Wang et al., 2011) and Stargazin (Letts et al., 1998; Menuz 
and Nicoll, 2008). CPT1C is proposed to play a similar role to FRRS1L in AMPA receptor 
biogenesis (Brechet et al., 2017). As might be expected, many phenotypic similarities can be 
found in knockouts of Cpt1c and Frrs1l. Carrasco et al (Carrasco et al., 2013) demonstrate 
that Cpt1c knockout mice have poor co-ordination, reduced latency to fall from a rotarod, ataxia 
and reduced grip strength. Conversely, the Cpt1c knockout mice show hypoactivity, whereas 
we demonstrate that Frrs1l-/- mice are hyperactive. It is possible that this inconsistency is due 
to the different methods of activity test measurement in the two studies, or differences in 
background strains. However, where both studies use SHIRPA assessment as a qualitative 
assessment of behaviour, there do seem to be differences in activity levels between the two 
strains. Furthermore Cpt1c knockout mice showed a consistent reduction in two separate 
tests, whereas Frrs1l-/- showed a consistent increase across two tests, indicating perhaps a 
true difference in phenotype. Interestingly, Cpt1c knockout mice also show reduced levels of  
AMPA receptor subunit proteins, with no change in AMPA receptor gene expression by qPCR, 
































that these two proteins are involved in the same process. Null mutations in mouse Shank3, a 
scaffold protein in the post synaptic density, results in abnormal foot placement and reduced 
latency to fall from a rotarod, both of which are seen in Frrs1l-/- mice. However Shank3 mice 
also show decreased locomotion which is contrary to the phenotype of Frrs1l-/- . The Stargazin 
mouse has a mutation in TARP-2 (stargazing), an auxiliary subunit of AMPA receptors, which 
causes a general decrease in AMPA receptor function and phenotypes that overlap with Frrs1l 
mutants, specifically ataxia and impaired co-ordination (Letts et al., 1998; Menuz and Nicoll, 
2008). Stargazin mice also have a similar change in glycosylation of GLUA2 as seen in Frrs1l-
/-. It is noticeable that one of the main features of patients with homozygous mutations in 
FRRS1L and in the stargazin mouse model is the presence of seizures. Some incidences of 
behavioural seizures were observed in several Frrs1l-/- mice (one mouse was seen to have 
tonic clonic seizures on one occasion, another mouse had a tonic clonic seizure from which it 
did not recover, and other mice were seen to freeze for extended periods) such behaviours 
were never observed in wild type control animals. We are aware of the limitations of the 
assessments conducted in this study and the need of future analysis. Further quantifiable 
evaluation of seizures is needed to understand the extent of the seizure phenotype in Frrs1l-/- 
mice. 
 
In summary, we provide evidence for the validity of the Frrs1l-/- mouse as a model of disease, 
expressing phenotypic features that resemble many of the clinical symptoms in patients.  At 
the molecular level we have demonstrated that FRSS1L has a fundamental role in AMPA 
receptor biology, impacting in the total AMPA receptor levels as well as a reduction in the 
proportion of AMPA receptors available at synapses. This mouse is potentially an important 
model not only to support the development of therapeutics for such patients, but also as a 
valuable resource to further understand the complexities of AMPA receptors and glutamate 
signalling in the brain. 
 
 
Materials and Methods  
Mice 
All mice (Mus musculus) were maintained and studied in accordance with UK Home Office 
legislation and local ethical guidelines issued by the Medical Research Council (Responsibility 
in the Use of Animals for Medical Research, July 1993; home office licenses 30/2890 and 
30/3384). Mice were fed ad libitum on a commercial diet (SDS Rat and Mouse No. 3 Breeding 
diet, RM3) and had free access to water (9–13 ppm chlorine). Mice were kept under controlled 

































Frrs1ltm1a/+  mice were derived from C57BL6/NTac ES cells (Skarnes et al, 2011).The null allele 
(tm1b) was created by carrying out an IVF using Frrs1ltm1a/+ sperm and C57BL6/NTac oocytes. 
Soluble cell permeable cre (TAT-Cre (Tat-NLS-Cre, HTNC, HTNCre), Excellegen, Rockville, 
USA) was added to two cell Frrs1ltm1a/+ embryos to generate the Frrs1ltm1b/+allele. The cre 
excises the selection cassette and exon 3 of the Frrs1l gene, creating a null allele 
(https://www.i-dcc.org/imits/targ_rep/alleles/14093/allele-image?simple=true.jpg). Following 
washing to remove the soluble cre, the IVF procedure was completed as normal. The 
Frrs1ltm1b/+ were crossed to C57BL6/NTac and then intercrossed to create Frrs1ltm1b/tm1b, 
Frrs1ltm1b/+ and Frrs1l+/+ cohorts. Hereafter Frrs1ltm1b/tm1b will be referred to as Frrs1l-/-. 
 
Behavioural phenotyping tests.  
For all behavioural phenotyping tests, mice were taken to the test room at least 20 minutes 
prior to the start of the test to acclimatise. Phenotyping equipment was cleaned with 70% 
ethanol/IMS or 2% Distel between tests.  
Investigators were blind to genotype during all phenotyping tests. 
All phenotyping except fear conditioning was carried out on female mice due to issues of 
reduced viability. SHIRPA, grip strength and home cage activity monitoring were assessed at 
3, 6 and 9 months. All other tests were carried out on only one occasion at the ages indicated 
below. For behavioural tests, sample size was calculated using power equations based on 
previous data obtained on C57BL/6NTac mice. Sample sizes in the later time points are 
smaller due to the loss of several mice with welfare concerns. 
 
Fear conditioning. Fear conditioning was carried out on a separate cohort of male mice prior 
to the rest of the study (n=7 C57BL/6NTac; n=8 Frrs1l+/-, n=7 Frrs1l-/-). These mice were part 
of the IMPC phenotyping pipeline, the remainder of the IMPC phenotyping data is published 
on the IMPC data portal (IMPC, http://www.mousephenotype.org/, Koscielny et al., 2014).  
 
Open Field Activity. Open field activity was used to assess locomotion in a novel environment. 
At 10 weeks of age (+/-1 week), mice were placed in square arenas (44x44cm) in a small 
testing room. A minimum of two and a maximum of four mice were tested at one time, one 
mouse per arena. Lighting was set at 150-200 lux. Mice were video tracked for 20 minutes and 
data analysed using Ethovision XT software (Noldus, Netherlands) and parameters such as 
distance moved, velocity and duration moving were recorded  in various zones over the entire 
20 minute period (Joyce et al., 2016). (n=7 Frrs1l +/+; n=10 Frrs1l -/-).  
 
SHIRPA. A semi-quantitative assessment was carried out using a modified SmithKline 
































protocol. Behaviour and dysmorphology parameters were recorded as previously described 
(Masuya et al., 2005) (n=8 Frrs1l +/+ ; n=9 Frrs1l -/- at three months,  n=8 Frrs1l +/+ ; n=9 Frrs1l 
-/- at 6 months, n=8 Frrs1l +/+ ; n=7 Frrs1l -/-at 9 months).  
 
Grip Strength. Grip strength was assessed at 13 weeks of age (+/-1 week) using the Grip 
Strength Test (BioSeb, Chaville, France). Readings were taken from all four paws, three times 
per mouse at each age, as per manufacturer’s instructions (Joyce et al., 2016). (n=8 Frrs1l +/+; 
n=8 Frrs1l -/- at three months,  n=8 Frrs1l +/+ ; n=8 Frrs1l -/- at 6 months, n=6 Frrs1l-/- n=6 Frrs1l+/+ 
at 9 months). 
 
Home cage analysis. Group housed animals were monitored as described (Bains et al., 2016). 
Briefly, group housed mice were tagged with RFID micochips at 9 weeks of age and placed in 
the Home Cage Analysis system (Actual Analytics, Edinburgh) which captured mouse 
behaviour using both video tracking and location-tracking using RFID co-ordinates (Bains et 
al., 2016). (n=8 Frrs1l +/+ ; n=8 Frrs1l -/- at all time points). 
 
Locotronic. Paw placement was analysed using Locotronic (Intelli-Bio, France) at 13 weeks of 
age (+/-1 week). Briefly, animals were assessed as they moved down a corridor with a 
horizontal ladder as its base. Animals were motivated to travel from a lighter starting area at 
one end to a darker finish area at the other end (bars: 3 mm diameter; spaced by 7 mm). 
Infrared sensors above and below each bar space recorded any errors of paw placement. 
Trials were discounted if the mouse took more than 30s to move to the finish after exiting the 
start area (n=8 Frrs1l +/+ ; n=7 Frrs1l -/-). 
 
Rotarod. To assess co-ordination and motor learning, 22-week-old mice (+/- 2 weeks) were 
placed on an accelerating rotarod (Ugo Basile), with rotor speed increasing from 4rpm up to 
40rpm over a five-minute period. The time taken for the mouse to fall from the rod was 
recorded. This was repeated three times on one day with a 15 minute inter trial interval 
(Corrochano et al., 2012) (n=8 Frrs1l +/+ ; n=9 Frrs1l -/-).  
 
Y-maze. A forced alternation y-maze test was used to evaluate short term working memory in 
mice at 14-20 weeks of age. Mice were placed in a y-maze with access to one arm blocked, 
they were then free to explore the start arm and the ‘familiar’ arm for ten minutes. Mice were 
returned to the home cage for a two minute inter trial interval, during which the maze was 
cleaned to remove odour cues. The mice were then returned to the maze, with access to all 
































software (Noldus, Netherlands)   (Sanderson and Bannerman, 2012). (n=7 Frrs1l +/+ ; n=7 
Frrs1l -/-). 
 
Motor function assessment by wheel running. For further assessment of motor function, 45-50 
week old mice were singly housed and placed in cages containing a running wheel as 
previously described (Mandillo et al., 2014) (TSE systems Bad Homburg, Germany). Number 
of rotations, time running, number of bouts and speed were measured. After two weeks with 
the standard wheel, this was replaced with a complex wheel which had specific rungs removed 
in order to test co-ordination and learning. Parameters were recorded for a further week (n=5 
Frrs1l +/+ ; n=5 Frrs1l -/-).  
 
Passive Infrared screen for immobility defined sleep (PIR) 
At 1 year, mice were analysed for circadian activity and immobility defined sleep using the 
COMPASS system as described (Brown et al., 2016). Mice were individually housed and data 
captured for 5 days in a 12:12 LD cycle, followed by 9 days in constant darkness. Data analysis 
was performed using custom python scripts and excels sheets, developed in house. Circadian 
analysis was performed by converting activity data from PIR to AWD files for analysis on 
Clocklab (Actimetrics, Illinois) or Actiwatch Sleep analysis software (CamNtech, Cambridge) 
(n=5 Frrs1l +/+ ; n=6 Frrs1l -/-). 
 
Quantitative PCR analysis 
RNA extraction from P0 brain tissue or cerebellum of 14 month old mice was performed using 
an RNeasy kit (Qiagen) (n=5 Frrs1l +/+ ; n=5 Frrs1l -/- at P0, n=4 Frrs1l +/+ ; n=4 Frrs1l -/- at 14 
months). cDNA synthesis was performed using the High Capacity cDNA RT kit (ThermoFisher 
Scientific) starting with 2µg of total RNA. cDNA for qPCR amplification was used at a final 
concentration of 10 ng per well. All the reactions were run in triplicate. Fast Sybr Green 
mastermix from ThermoFisher Scientific was used and the reactions had a final volume of 
20µl. Primers were at a final concentration of 360nM. Primers were designed to span exon-
exon boundaries and are listed in Supplemental Table 1. Fold changes were calculated using 
the 2-ddCt method using the 7500 Software v2.0.6 and normalized using S16 endogenous 
reference genes relative to WT genotype (Livak and Schmittgen, 2001).  
 
Immunoblot analysis 
Adult cerebellum or P0 whole brains were bisected and one fraction homogenized in RIPA 
buffer (150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris pH 7.5) with 
phosphatase and protease inhibitor cocktails (Roche), using lysing matrix tubes D (MP 
































centrifuged at 12,000 g 4°C for 20 min. 30 μg of soluble fractions were resolved by SDS–
PAGE (NUPAGE system, Invitrogen) and transferred to Nitrocelulose membranes (Millipore) 
for western-blot analysis. The following primary antibodies were used: rabbit monoclonal anti-
b-actin (1/3000 Sigma A2066); mouse anti-α tubulin (1/3000 Sigma T9026), rabbit anti-GLUA1 
(1/1000 Millipore 1504) mouse anti-GLUA2 (1/800 Millipore MAB397), rabbit anti-GLUA4 
(1/1000 Millipore AB1508), mouse anti-CAMKII (1/200 Proteintech 20665-1) mouse anti- 
SNAP25 (1/500 Biolegend 836304), rabbit anti- PSD-95 (1/1000 Cell Signalling 3450T), and 
mouse anti-GRIN1 (for NMDA receptor, 1/1000 Novus, NB300-118).  
Protein was visualized using anti-mouse (P/N 926-68070) or anti-rabbit (P/N 926-32211) 
secondary antibodies IRDye® (Li-Cor Biosciences) at 1:10000 dilutions and quantified using 
the scanning infrared Odyssey imaging system CX (Li-Cor Biosciences).  




Bisected adult cerebellum was homogenised in RIPA buffer as above. 60ug of soluble fraction 
was de-natured with glycoprotein denaturing buffer for 10 minutes at 100 degrees, followed by 
immediate immersion in ice. Samples were divided into three aliquots and glycobuffer added, 
followed by Endo-H (QABio, E-EH02), PNGase (New England Biolabes, P0704S) or water. All 
samples were incubated at 37 degrees for 1 hour. Half of each sample, containing 10μg of 
protein, was resolved by SDS–PAGE (NUPAGE system, Invitrogen) and transferred to 
Nitrocellulose membranes for Western blot analysis.  
 
Post-Synaptic Fractionation enrichment.  
Synaptic fractionation was conducted following a modified protocol using a single cerebral 
hemisphere homogenized using a Dounce homogenizer in Syn-PER™ Synaptic Protein 
Extraction Reagent (Thermo Scientific, IL, USA) with phosphatase and protease inhibitor 
cocktails (Roche). Homogenates were cleared by centrifugation at 1200 x g for 10 min and 
then at 15000 x g for 20 min at 4 degrees. The supernatant contains the cytosolic fraction and 
the pellet the crude synaptosomal fraction. The pellet was resuspended in syn-PER lysis buffer 
with 0.1mM CaCl2 and 2% Triton X-100, 40mM Tris, pH6  and incubated on ice, with gentle 
agitation for 30 minutes. Following a centrifugation at 40,000 x g for 30 minutes at 4°C, the 
pellet was washed with 1% Triton X-100, 20mM Tris, pH6. Then the sample was centrifuged 
again, resuspended in 1% Triton x-100, 20mM Tris, pH8 and incubated on ice with gentle 
agitation for 30 minutes. After another centrifugation at 40,000 x g for 30 minutes at 4°C the 
pellet, containing the post-synaptic density, was resuspended in 1% Triton x-100, 20mM Tris, 
































subsequently centrifuged at 15,000 x g for 30 minutes, at 4°C. The pellet containing the post-
synaptic fraction was resuspended in 5 % SDS. After protein quantification with a DC assay 
(BioRad), 15 μg of protein from the post-synaptic fraction and 20 μg from the cytoplasmic 
fraction were resolved in precast 3-8% SDS-PAGE gels and transferred to Nitrocellulose 
membrane (Invitrogen) for Western blot analysis.  
 
Synapse Counts 
Formalin fixed wax embedded sections from adult whole brain were dewaxed, the antigen was 
unmasked using sodium citrate buffer solution (ph 6.0) at 80 °C for 30 minutes. Sections were 
next washed in phosphate-buffered saline (PBS, Ph 7.4) and processed for 
immunofluorescence. After a blocking step in PBS containing 0.05% Triton X-100 and 10% 
normal goat serum (NGS), sections were incubated overnight at 4 °C with the antibodies anti-
VGLUT1 (1:200, Synaptic System. Antibody was diluted in PBS with 3% normal goat serum 
and 0.05% Triton X-100. Sections were then washed in PBS (4 x 10 min) and incubated for 1 
h at room temperature with a secondary anti-rabbit antibody conjugated with Alexa Fluor 488 
(Invitrogen). After several PBS rinses, sections were mounted on glass slides and observed 
with a Zeiss LSM 700 confocal microscope (Carl Zeiss AG). Confocal z-stacks covering the 
whole depth of the slices (1024 x 1024 pixels) spaced by 1.05 µm were acquired at 63 x. 
VGLUT1 positive puncta were analysed on confocal images using Fiji software. Caudal 




Electroencephalography (EEG) measurements were conducted in male mice, around 30g in 
weight, and age between 4 and 6 months (n=3 Frrs1l-/-, n=2 Frrs1l/+/+, and n=2 C57BL/6NTac). 
Wireless EEG transmitters (A3028A, Open Source Instruments, USA) were implanted 
subcutaneously with a subdural intracranial recording electrode positioned above the right 
frontal lobe (0.5mm anterior to Bregma and 0.5mm medial-lateral). The second electrode was 
implanted in between the frontal and occipital lobes, above the right motor cortex (1 – 1.5mm 
posterior to Bregma and 3 - 4 mm medial-lateral). The animals were able to freely move while 
assessed in their home-cage environment for 5 to 21 days. EEG was recorded after at least 3 
or more post-surgery recovery days to ensure no residual anaesthesia effect.  Dataquest 
software (Neuroachieve v. 8.5.20, Open Source Instruments, USA) was used to acquire and 
analyse the EEG data. EEG activity was sampled at 512 Hz at between 0.3Hz and 160Hz. 
Representative high amplitude signals were screened visually and fast fourier transform was 


































Estimates of Mendelian inheritance of all genotypes were assessed using a chi-squared test. 
Analysis of categorical data from SHIRPA was completed using Fishers exact test. Grip 
strength test, rotarod, home cage analysis, time spent asleep, sleep bouts over time, sleep 
fragmentation and motor function wheel running data were assessed using repeated 
measures analysis of variance (ANOVA) with Sidak post-hoc analysis. Body weight was 
assessed using two-way ANOVA with post hoc comparisons. Forced alternation y-maze data 
were assessed using the Student’s t-test. Open field data were analysed using the Student’s 
t-test with Welch’s correction for unequal variance. Graphpad Prism and R software were used 
for statistical analysis. 
All graphs show absolute values with mean and standard deviation, unless specified.  
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Fig. 1 Frrs1l-/- have reduced survival, decreased body weight, coordination and limb grasping 
abnormalities. Frrs1l-/- are born in accordance with predicted mendelian ratios (P=0.43) and show no significant 
difference to expected numbers. Pups were genotyped at weaning and greatly reduced numbers of Frrs1l-/- were 
found (p<0.0001 (A)). Data analysed by chi-square test. Frrs1l-/- have significantly lower weight from 6 months of 
age but show a similar weight curve and no deterioration (B). Data analysed by two way ANOVA with post-hoc 
comparisons (*p<0.05, **p<0.01, ***p<0.001).  n=7 Frrs1l +/+ from 2-11 months and n=5 Frrs1l +/+ at 12 months, n=9 
Frrs1l -/- at 2-4 months, n=8 Frrs1l-/-at 5 months, n=7 Frrs1l-/- at 6-8 months, n=6 Frrs1l-/- at 9-12 months. Frrs1l-/-  
show increased incidence of limb grasping (p<0.01 at 3, 6 and 9 months), representative image (C).  Grip strength 
































Data analysed by repeated measures ANOVA followed by Sidak multiple comparisons test, data show is average 
of three trials at each time point.  n=8 Frrs1l +/ ; n=8 Frrs1l -/- at 3 and 6 months, n=6 Frrs1l+/+ ; n=6 Frrs1l-/- at 9 
months. Misplacement of feet on the Locotronic horizontal ladder results in an increased number of errors in Frrs1l-
/- (E), n=8 Frrs1l +/+; n=7 Frrs1l -/- analysed using general linear model with Poisson distribution. Frrs1l-/- have a 
significantly decreased latency to fall from an acceleration rotarod (p<0.01) (n=8 Frrs1l +/+ ; n=8 Frrs1l -/-). Data 
analysed by repeated measures ANOVA.  Frrs1l-/- display no difference in wheel running on simple wheels but show 
a significant difference when changed to complex wheels, analysed using ANOVA followed by Sidak multiple 
comparisons test n=5 Frrs1l +/+ ; n=5 Frrs1l -/-(G).(*p<0.05, **p<0.01, ***p<0.001). Body weight (B) and Wheel 





























































 Fig. 2 Deletion of Frrs1l causes hyperactivity, working memory deficits and abnormal sleep pattern. An 
increase in distance moved is apparent in the home cage both during the light phase and the dark phase at 10 
weeks old (p<0.05), and in the dark phase only at 6 months and 9 months (p<0.01) (A and B). Data analysed using 
ANOVA followed by Sidak multiple comparisons test, n=8 Frrs1l+/+, n=8 Frrs1l-/-. Total distance moved (C) and 
velocity in an open field arena (D) are significantly increased in Frrs1l-/- when compared to Frrs1l+/+ controls 
(p<0.01). Data analysed by t-test. n=8 Frrs1l+/+ ; n=8 Frrs1l-/-. (E) Frrs1l-/- do not show a preference for the novel 
arm in a forced alternation y-maze task. Frequency of Frrs1l-/- entry into the novel arm stays at chance level, while 
Frrs1l+/+ show increased exploration. Data are ratio of frequency in novel arm (frequency in novel arm/(frequency 
































/- exhibit abnormal immobility defined sleep behaviour. Frrs1l-/- show decreased total time asleep in a 24 hour period, 
with the total time asleep in the dark phase being significantly reduced (p<0.001), Sleep bout length is significantly 
reduced (G). Demonstrating that Frrs1l-/- have a fragmented sleep pattern, with less time asleep overall and shorter 
sleep bouts Frrs1l+/+; n=5, Frrs1l-/- n=6 (*p<0.05, **p<0.01, ***p<0.001). For average sleep bout length (G) data are 
mean and standard deviation. A separate cohort of Frrs1l-/- males, assessed as part of the IMPC pipeline, do not 
show an increase in freezing in response to tone during a cued fear conditioning paradigm. (H) Difference in pre-










































Fig. 3. Encephalographic abnormalities are seen in Frrs1l-/-animals. EEG sample extracted from a FRRS1L 
wild type litter mate control (A). Representative traces from different Frrs1-/- animals showing repeated runs of 


































Fig. 4. Frrs1l deficiency leads to changes in AMPA receptor subunit levels with no change in gene 
expression. qPCR for Gria1-4 show no changes between Frrs1l-/- and wild type controls for Gria1 and Gria2, with 
only slight but significant changes for Gria3 and Gria4 (p<0.05 and p<0.001 respectively) (A). GLUA1, GLUA2 (B) 
and GLUA4 (C) immunoreactivity are all significantly lower in Frrs1l-/- adult cerebellum (P<0.001, P<0.01 and 
P<0.001 respectively). The pattern of GLUA2 and GLUA4 differ between Frrs1l-/- and wild-type controls, with a 
diffuse band present for GLUA2 in wild-types but only a thin band in Frrs1l-/-, GLUA4 blots also indicate changes in 
immunoreactive band mobility. Other synaptic proteins, PSD-95, SNAP25 (D) and CAMKII (E) and NMDAR 
(GRIN1) (F), remain unchanged between Frrs1l-/- and wild-type controls. Data analysed using t-test (Frrs1l+/+ ; n=4, 




























































Fig. 5 AMPA receptors have altered glycosylation state and are mislocalised in the cytoplasm in  
Frrs1 mice. Posttranslational glycosylation state is altered in Frrs1l-/-, demonstrated by differential digestion with 
glycosylation sensitive enzymes when compared to wild-type littermates. Frrs1l-/- show greater sensitivity of GLUA2 
and GLUA4 digestion with ENDO-H (p<0.01), approximately 18% of wild-type GLUA2 and GLUA4 is digested 
compared to approximately 65% and 45% respectively in Frrs1l -/-. Localisation of AMPA receptors is altered, with 
increased amount of AMPA receptor in the cytoplasm rather than the synapse in Frrs1l-/-. GLUA1 proportions in the 
cytoplasm and the synapse were not altered, and overall levels of GRIN1 were unchanged between Frrs1l-/- and 
wild type controls.  Data analysed using students t-test (n=3 Frrs1l-/-, n=3 Frrs1l+/+). Percentage of total GLUA2 and 

































Table 1 Longitudinal SHIRPA analysis shows co-ordination deficits from an early age. From 3 months of age 
Frrs1l-/- show significantly increased activity in the viewing jar, increased incidence of feet falling through the bars, 
abnormal gait, limb grasping and inability to climb down a wire mesh without slipping (negative geotaxis). 
Deterioration up to the age of 9 months is not noticeable except that there is an increase in falling during negative 
geotaxis. Number of animals with each condition in relevant columns (*p<0.05, **p<0.01, ***p<0.001) 
9 month 3 month 
Frrs1l+/+ Frrs1l-/-
6 month 
Frrs1l+/+ Frrs1l-/- Frrs1l+/+ Frrs1l-/-
8   4 8    3 8 2 Normal activity 
Increased activity 0   5* 0   5* 0 5** 
8 1 8 3 7 0 Feet on bars 
Feet falling through bars 0 8*** 0   5* 0 7*** 
7 2 7 0 7 0 Normal gait 
Abnormal gait 1 7* 1     8** 0 7*** 
8 2 7 0 7 1 Limb grasp absent 
Limb grasp present 0 6** 1 8** 0 6** 
8 3 7 4 7 0 
0 5 1 1 0 3 
Normal climbing 
Slips/loss of grip 
































Table S1.  Primer sequences for gene expression analysis by qPCR. 
Gene Primer sequence 
Gria 1 Fwd TCCCCAACAATATCCAGATAGGG 
Rev AAGCCGCATGTTCCTGTGATT 
Gria 2 Fwd TTCTCCTGTTTTATGGGGACTGA 
Rev CTACCCGAAATGCACTGTATTCT 
Gria 3 Fwd ACCATCAGCATAGGTGGACTT 
Rev ACGTGGTAGTTCAAATGGAAGG 
Gria 4 Fwd GTTTTCTGGATTTTGGGGACTCG 
Rev AAGAGACCACCTATTTGAACGC 
Frrs1l Exon 1-2 Fwd CCAGCGAGTTCTACGACCTG 
Rev TCCCGTATCTGAAGCATCCC 
Frrs1l Exon 2-3 Fwd GTGGACCCATTCGCCAAAAT 
Rev CGCCTATCATCCGGTAGCTA 
Frrs1l Exon 4-5 Fwd TGTTCCCAGGGATGAAACGA 
Rev AAGCCGGTGGAGAGTCTATG 





























































Fig. S1.  Frrsl1-/- mice have no expression of Frrs1l in both P0 pups and adults brain (A and 
B). No changes in Gria expression are seen at P0 in Frrsl1-/-  mice compared to wild-type 
controls.



































Open field - Total distance moved



































































































Fig. S2. Frrsl1-/- mice show changes in some but not all anxiety related parameters in open field.




































































































































Frrs1l +/+ Frrs1l -/-
Frrs1l +/+ Frrs1l -/- Frrs1l +/+ Frrs1l -/-
Frrs1l +/+ Frrs1l -/- Frrs1l +/+ Frrs1l -/-











































































































Fig. S3. Frrs1l-/- P0 brains show alterations in levels of AMPA receptor proteins. Frrs1l-/- P0 brains have 
significantly less GLUA1 (p<0.01), whilst GLUA2 and GLUA4 total levels are unchanged between Frrs1l-/- and 
wild-types. However two distinct bands are present in wild-type GLUA2 with the upper band significantly reduced 
in Frrs1l-/- (p<0.001). Levels of other synaptic proteins PSD95, SNAP25 and CAMKII are the same in both Frrs1l-/- 
and wild types.  Data analysed using t-test (n=5 Frrs1l-/-, n=5 Frrs1l+/+) for all except GLUA2 (n=3 Frrs1l-/-, n=4 
Frrs1l+/+) and GLUA4 (n=4 Frrs1l-/-, n=4 Frrs1l+/+).  













































































Fig. S4. No differences were found in excitatory synapse number in the hippocampus of Frrs1l-/- mice compared to 
C57BL/6NTac controls. 
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